Beleave Inc. (CSE: BE; OTCQX: BLEVF) in reference to its previously announced Non-Brokered Private Placement dated April 24, 2018, (the “Non-Brokered Offering“) is pleased to announce that it has received binding commitments for total proceeds of $5,000,000 at a price of $1.75 per unit. Subject to customary closing conditions, including CSE approval, the Non-Brokered Offering is now expected to close on or about April 26, 2018.
“The company is pleased to welcome a new group of investors, bolster the treasury and add to the companies working capital for future endeavours,” commented Beleave CEO Andrew Wnek.
Each unit is comprised of one common share of the Company (a “Common Share“) and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share of the Company at an exercise price of $2.25 for a period of 24 months from the date of issuance of the Warrant, subject to accelerated expiry in the event that the ten-day volume weighted average price of the Common Shares on the Canadian Securities Exchange (the “CSE“), or other exchange or quotation system where the Company’s shares are listed and where a majority of the trading volume of the Common Shares occurs, equals or exceeds $3.00.
About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located near Hamilton, Ontario.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
